SCHEMBL2697137

SCHEMBL2697137

O=C(c1ccc(CN2CCC3(CCN(Cc4ccc(C(F)(F)F)cc4)CC3)C2)cc1)N(Cc1ncc[nH]1)Cc1ncc[nH]1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.73
MGLL Q99685 1/20 0.48
USP2 O75604 7/20 0.45
CYP3A4 P08684 7/20 0.45
CYP2C9 P11712 4/20 0.45
CYP2C19 P33261 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
TSHR P16473 4/20 0.45
CYP2D6 P10635 3/20 0.45
CYP1A2 P05177 2/20 0.45
ALDH1A1 P00352 1/20 0.44
HIF1A Q16665 3/20 0.43
GPR183 P32249 4/20 0.43
EPAS1 Q99814 1/20 0.43
KDM1A O60341 1/20 0.42
MAOB P27338 1/20 0.42
RCOR1 Q9UKL0 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
OPRD1 P41143 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2693485 0.92 CXCR4 (0.67) CXCR4USP2CYP3A4CYP2C9CYP2C19
SCHEMBL1795793 0.91 CXCR4 (0.78) CXCR4CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL1794482 0.90 CXCR4 (0.77) CXCR4USP2CYP3A4CYP2C9CYP2C19
SCHEMBL1792729 0.90 CXCR4 (0.77) CXCR4USP2CYP3A4CYP2C9CYP2C19
SCHEMBL1792872 0.89 CXCR4 (0.78) CXCR4CYP3A4CYP2C19TSHRCYP2D6
SCHEMBL2694920 0.88 CXCR4 (0.67) CXCR4USP2CYP3A4ALDH1A1KDM1A
SCHEMBL2693219 0.88 CXCR4 (0.80) CXCR4CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL1795594 0.88 CXCR4 (0.80) CXCR4USP2CYP3A4CYP2C9CYP2C19
SCHEMBL1791846 0.87 CXCR4 (0.78) CXCR4CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL2694661 0.87 CXCR4 (0.79) CXCR4MGLLUSP2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US claimed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP claimed
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885MGLL 3385/4885USP2 4876/4885
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 CXCR4 1/4885MGLL 3340/4885USP2 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.